Becton, Dickinson and Company BDX

183.82 4.59 2.56% as of 25 Sep
Market cap
$48.8B
P/E
55.4×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

Becton, Dickinson and Company (BDX) EV/Sales

As of 25 September 2026, Becton, Dickinson and Company (BDX) trades at a EV/Sales of 2.8×. Over the past ten years it has ranged from 2.4× (June 2026) to 5.2× (January 2018); the current reading is higher than 11% of that period. That is below the Medical Instruments & Supplies industry median of 3.1× and below the Healthcare sector median of 3.6×.

EV/Sales, daily

Annual

Period EV/Sales Change
FY2025 2.7× (22.53%)
FY2024 3.5× (4.94%)
FY2023 3.7× 10.80%
FY2022 3.3× (8.28%)
FY2021 3.6× (9.19%)
FY2020 4.0× (1.31%)
FY2019 4.0× (7.81%)
FY2018 4.4× 41.56%
FY2017 3.1× 1.77%
FY2016 3.0× 2.66%

Quarterly

Period EV/Sales Change
Jun 2026 2.4× (7.27%)
Mar 2026 2.6× (3.78%)
Dec 2025 2.7× 0.10%
Sep 2025 2.7× (3.48%)
42 more quarters

Against its own ten years

Low 2.4× High 5.2×
Ten-year median 3.5×
Current reading's percentile 11

EV/Sales against peers

Company EV/Sales
MDLN Medline Inc. compare 1.3×
BAX Baxter International Inc. compare 1.7×
SOLV Solventum Corporation compare 2.4×
BDX Becton, Dickinson and Company 2.8×
ALC Alcon compare 3.2×
RMD ResMed Inc. compare 5.5×
WST West Pharmaceutical Services, Inc. compare 7.8×
ISRG Intuitive Surgical, Inc. compare 12.5×
RGEN Repligen Corporation compare 13.4×
Medical Instruments & Supplies industry median 3.1×
Healthcare sector median 3.6×
Market median 2.2×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on BDX